{"id":"W4386387581","doi":"10.1007/s11523-023-00987-1","title":"Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial","year":2023,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; Ono Pharmaceutical; Memorial Sloan-Kettering Cancer Center; Bristol-Myers Squibb","keywords":"Nivolumab; Medicine; Ipilimumab; Renal cell carcinoma; Placebo; Nephrectomy; Internal medicine; Adjuvant; Oncology; Adjuvant therapy; Kidney cancer; Clinical trial; Cancer; Surgery; Immunotherapy; Kidney; Pathology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004184816,0.0005768373,0.002927763,0.001290189,0.0001960681,0.0000268179,0.00036195,0.0006690525,0.0007114696],"category_scores_gemma":[0.0007241075,0.0004735655,0.0009997744,0.001278095,0.0009073537,0.00011531,0.0002787065,0.0008029089,0.0002468076],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001558914,"about_ca_system_score_gemma":0.002579333,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006114048,"about_ca_topic_score_gemma":0.0001675277,"domain_scores_codex":[0.9934477,0.001416497,0.00155507,0.001023574,0.001071327,0.001485827],"domain_scores_gemma":[0.9928762,0.0043649,0.0004780614,0.0009360838,0.0007643797,0.0005803716],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9729884,0.001540491,0.00002651248,0.0005006477,0.0006436632,0.001694228,0.00112127,0.00003920258,0.006114898,0.00006995045,0.01369233,0.001568364],"study_design_scores_gemma":[0.9187047,0.01941757,0.00001818584,0.0000928947,0.001304079,0.0000456092,0.0004491053,0.002938949,0.03391765,0.0002157193,0.02254076,0.0003547865],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9731466,0.00268675,0.0002210593,0.0007919429,0.001633249,0.01521273,0.0001736573,0.0002549028,0.005879077],"genre_scores_gemma":[0.9804446,0.0002141002,0.00257718,0.00009116631,0.0009080499,0.008176319,0.001042654,0.0001539837,0.006391986],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05428374,"threshold_uncertainty_score":0.9997716,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1294819005494149,"score_gpt":0.4061370170159111,"score_spread":0.2766551164664962,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}